Edison Investment Research is terminating coverage on Achillion Pharmaceuticals (ACHN). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Achillion Pharmaceuticals - Termination of coverage
- Published:
12 Nov 2017 - Author:
- Pages:
Edison Investment Research is terminating coverage on Achillion Pharmaceuticals (ACHN). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.